Evaluation scales for Parkinson's disease;Les echelles d'evaluation dans la maladie de Parkinson

Revue Neurologique

Volumn 156, Issue SUPPL. 2 BIS, 2000, Pages 52-62

  Krystkowiak, P ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKINESIA; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DISABILITY; DYSARTHRIA; DYSPHAGIA; FUNCTIONAL ASSESSMENT; HUMAN; INVOLUNTARY MOVEMENT; MUSCLE RIGIDITY; PARKINSON DISEASE; QUESTIONNAIRE; RATING SCALE; TARDIVE DYSKINESIA; TREMOR;

HUMANS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE;

EID: 0033942197     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (90)

1. AUZOU P, OSZSANCAK C, JAN M, LEONARDON S, MENARO JF, GAILLARD MJ, EUSTACHE F, HANNEQUIN D. (1998). Evaluation clinique de la dysarthrie: présentation et validation d'une méthode. Revue Neurologique, 154: 6-7, 523-530.
2. BAAS II, STECKER K, FISCHER PA. (1993). Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease. J Neural Transm Park Dis Dement Sect, 1: 45-61.
3. BECK AT. (1978). Beck Depression Inventory. San Antonio, Tex: Psychological Corp.
4. BERGNER A., BOBBITT RA, CARTER WB, GILSON BS. (1981). The Sickness Impact Profile: Development and final revision of Health Status Measure. Med Care, 29: 787-805.
5. BROWN RG, MACCARTHY B, JAHANSHAHI M, MARSDEN CD. (1989). Accuracy of self-reported disability in patients with parkinsonism. Arch Neurol, 46: 955-959.
6. CALNE S, SCHULZER M, MAK E, GUYETTE C. et al. (1996). Validating a quality of life rating scale for idiopathic Parkinsonism: Parkinson's Impact Scale (PIMS). Parkinsonism & Related Disord, 2: 55-61.
7. CANTER CD, DE LA TORRE A, MIER M. (1961). A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis, 133: 143-147.
8. CHERNEY LR, CANTIERI CA, PANELL JJ. (1986) R I C clinical evaluation of dysphagia. Maryland: Aspen systems corporation.
9. CLARKE CE, GULLAKSEN E, MACDONALD S, LOWE F. (1998). Referral criteria for speech and language therapy assessment of dysphagia caused by idiopathic Parkinson's disease. Acta Neurol Scand, 1: 27-35.
10. CUTSON TM, SLOANE R, SCHENKMAN M. (1999). Development of a clinical rating scale for persons with Parkinson's disease. J Am Geriatr Soc, 47 (6): 763-764.
11. DE BODT MS, WUYTS FL, VAN DE HEYNING PH, CROUX C. (1997). Test-retest study of the GRBAS scale: influence of experience and professional background on perceptual rating of voice quality. J Voice, 11(1): 74-80.
12. DE BOER AGEM, WIJKER W, SPEELMAN JD, DE HAES JCJM. (1996). Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry, 61: 70-74.
13. DEFER GL, WIDNER H, MARIE RM, REMY P, LEVIVIER M. (1999). Core Assessment Program for Surgical Interventional Therapies in Parkinson's Disease (CAPSIT-PD). Mov Disord, 14, 4: 572-584.
14. DEJONCKERE PH. (1986). Technique de base d'évaluation de la voix, Cabay, Louvain-la-Neuve.
15. DUVOISIN RC. (1971). The evaluation of extrapyramidal disease. In De Ajuriaguerra J, Gauthier G, eds. Monoamines noyaux gris centraux et syndrome de Parkinson. Georg & Cie, Geneva : Georg & Cie, 313-325.
16. ENDERBY P. (1983). Frenchay Dysarthria Assessment, College Hill Press.
17. EVERITT BS, HAND D, BARRIE MA, et al. (United Kingdom Bromocriptine Research Group). (1989). Bromocriptine in Parkinson's disease: a double-blind study comparing "low-stow" and "high-fast" introductory dosade regimens in de novo patients. J Neurol Neurosurg Psychiatry, 52: 77-82.
18. FAHN S, ELTON RL. and Members of UPDRS Development Committee. (1987). Unified Parkinson's disease rating scale. In Fahn S, Marsden CD, Calne DB, eds. Recent Developments in Parkinson's Disease. Vol 2, London:. Macmillan Health Care Information, Florham Park Macmillan, 1987: 153-163.
19. FAHN S, TOLOSA E, MARIN C. (1988). Clinical rating scale for tremor. In Jankovic J, Tolosa E eds. Parkinson's disease and movement disorders. Munich, Urban, and Schwarzenberg, pp. 225-234.
20. FERRERI M, COUSIN J, RUFFIN JC, ALBI JM. (1986) Validation du diagramme HARD par le MADRS. Encéphale, 12: 343-50.
21. FITZPATRICK R, PETO V, JENKINSON C, GREENHALL R, HYMAN N. (1997). Health-related quality of life in Parkinson's disease: a study of outpatient clinic attenders. Mov Disord, 6: 916-922.
22. FOLSTEIN MF, FORLSTEIN SE, MCHUGH PR. (1975). Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res, 12: 189-198.
23. GEMINIANI G, CESANA BM, TAMMA F. et al. (1991). Interobserver reliability between neurologists in training of Parkinson's disease rating scales. A multicenter study. Mov Disord, 4: 330-335.
24. GINANNESCHI A, DEGL'INNOCENTI F, MAGNOLFI S. et al. (1988). Évaluation of Parkinson's disease: reliability of three rating scales. Neuroepidemiology, 7: 38-41.
25. GLOZMAN JM, BICHEVA KG, FEDOROVA NV. (1998) Scale of Quality of Life of Care-Givers (SQLC). J Neurol, 245, Suppl 1: S39-41.
26. GOETZ CG, STEBBINS GT, SHALE HM. et al. (1994). Utility of an objective Dyskinesias rating scale for Parkinson's disease: inter- and intra-rater reliability assessment. Mov Disord, 9: 390-394.
27. GOETZ CG. (1999). Rating scales for Dyskinesias in Parkinson's disease. Mov Disord, 14, Suppl 1: 48-53.
28. GUY W. (1976). ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US Government Printing Office.
29. HAMILTON MA. (1960). A rating scale for depression, J Neurol Neurosurg Psychiatry, 23: 56-62.
30. HAMILTON MA. (1959). The assessment of anxiety states by rating. Br J Med Psychol, 32: 50-55.
31. HARIZ GM, BEHGENHEIM AT, HHARIZ MI, LINDBERG M. (1998). Assessment of ability /disability in patients treated with chronic thalamic stimulation for tremor. Mov Disord, 13: 78-83.
32. HELY MA, CHEY T, WILSON A (1993). Reliability of the Columbia scale for assessing signs of Parkinson's disease. Mov Disord, 4: 466-472.
33. HENDERSON L, KENNARD C, CRAWFORD TJ, et al. (1991). Scales for rating motor impairment of Parkinson's disease: studies of reliability and convergent validity. J Neurol Neurosurg Psychiatry, 54: 18-24.
34. HOBSON P, MEARA J. (1999). The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing, 1: 39-43.
35. HOEHN MM, et YAHR MD. (1967). Parkinsonism : onset progression and mortality. Neurology, 17: 427-442.
36. HOFF JI, VAN HILTEN BJ, ROOS RAC. (1999). A review of the Assessment of Dyskinesias. Mov Disord, 14, 5: 737-743.
37. JENKINSON C, WRIGHT L, COULTER A (1993). Quality of life measurement in health care. A review of measures and population norms for the UK SF-36. Oxford, Health Services Research Unit. Oxford University.
38. JENKINSON C, LAYTE R. (1997). Development and testing of the UK SF-12 (short form health survey. J Health Serv Res Policy, 2 (1): 14-18.
39. KATZ S, DOWNS TD, CASH HR, GROTZ RC. (1970). Progress in developement of the index of ADL. Gerontologist, 10: 20-30.
40. KENNARD C, MUNRO AJ, PARK DM. (1984) The reliability of clinical assessment of Parkinson's disease. J Neurol Neurosurg Psychiatry, 47: 322-323.
41. KENNEDY G, PRING T, FAWCUS R. (1993) No place for motor speech acts in the assessment of dysphagia? Intelligibility and swallowing difficulties in stroke and Parkinson's disease patients. Eur J Dis Comm, 28: 213-226.
42. KURLAN R, RUBIN AJ, MILLER C, RIVERA-CALIMLIM L, CLARKE C, SHOULSON I. (1986). Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol, 20: 262-265.
43. LANGSTON JW, WIDNER H, GOETZ CG, BROOKS D, FAHN S, FREEMAN T, WATTS R (1992). Core assessment program for intracerebral transplantations (CAPIT). Mov Disord, 7: 2-13.
44. LARSEN TA, CALNE S, CALNE DB. (1984). Assessment of Parkinson's disease. Clin Neuropharmacol, 7: 165-169.
45. LAWTON MP, BRODY EM. (1969). Assessment of older people: self maintaining and instrumental activities of daily living. Gerontologist, 9: 179-186.
46. LIEBERMAN A. (1974). Parkinson's disease: a clinical review. Am J Med Sci, 277: 66-80.
47. LIEBERMAN A, DZIATOLOWSKI M, GOPINATHAN G, KUPERSMITH M, NEOPHYTIDES A, KOREIN J. (1980) in Goldstein M, Calne DB, Lieberman A, Thorner MD, eds. Ergot compounds and Brain Function. New York, NY: Raven Press, 277-286.
48. LIMOUSIN P, SPEELMAN JD, GIELEN F, JANSSENS M. (1999). Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry, 3: 289-296.
49. LONGSTRETH WT, NELSON L, LINDE M, MUNOZ D. (1992). Utility of Sickness Impact Profile in Parkinson's disease. J Geriatr Psychiatry Neurol, 5: 142-148.
50. MAC DOWELL FH, MARKHAM CH, LEE JE, et al. (1971). The clinical use of levodopa in Parkinson's disease. In Mac Dowell FH, Markham CH. Eds: recent advances in parkinson's disease. Philadelphia, FA DAVIS Company, 175-202.
51. MCHORNEY CA, WARE JE JR, LU JF, SHERBOURNE CD. (1994). The MOS 36-item short form health survey (SF-36): III. Tests of data quality, scaling assumptions and reliability across diverse patient groups. Med Care, 32: 40-66.
52. MAC RAE C, O'BRIEN C, FREED C. (1996). Quality of life among persons receiving neural implant surgery for Parkinson's disease. Mov Disord 11: 605-606.
53. MARCONI R, LEFEBVRE-CAPARROS D, BONNET AM, VIDAILHET M, DUBOIS B, AGIDY. (1994). L-Dopa induced dyskinesia in Parkinson's disease: phenomenology and pathophysiology. Mov Disord, 9: 2-12.
54. MARKHAM CH. (1971). The choreoathetoid movement disorder induced by levodopa. Clin Pharmacol Ther, 12: 340-343.
55. MARKHAM CH, DIAMOND SG. (1981). Evidence to support early levodopa therapy in Parkinson's disease. Neurology, 31: 125-131.
56. MARTINEZ-MARTIN P. (1993). Rating scales in Parkinson's disease. In Jankovic J, Tolosa E, eds. Parkinson's disease and movement disorders, 2nd edn. Williams and Wilkins, Baltimore, 281-292.
57. MARTINEZ-MARTIN P, GIL-NAGEL A, GHACIA LM, GOMEZ JB, MARTINEZ-SARRIES J, BERMEJO F, et al. (1994). Unified Parkinson's Disease rating Scale characteristics and structure. Mov Dis, 9: 76-83.
58. MARTINEZ-MARTIN P. (1997). A new clinical tool for gait evaluation in Parkinson's disease. Clin Neuropharmacol, 20 (3): 183-194.
59. MARTINEZ-MARTIN P, GIL-NAGEL A, MORLAN GRACIA L, BALSEIRO GOMEZ J, MARTINEZ-SARRIES FJ, BERMEJO F, DEL SER QUIJANO T, and the Cooperative Multicentric Group. (1995). Intermediate Scale for Assessment of Parkinson's disease: characteristics and structure. Parkinsonism and Related Disorders, 1: 97-102.
60. MATTIS S. (1988). Dementia Rating Scale. Odessa, Fla: Psychological Assessment Resources.
61. MONTGOMERY SA, ASBERG M. (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry, 134: 322-389.
62. MONTGOMERY GK, REYNOLDS NC JR, WARREN RM. (1985). Qualitative assessment of Parkinson's disease: study of reliability and data reduction with an abbreviated Columbia scale. Clin Neuropharmacol, 8: 83-92.
63. MOURADIAN MM, JUNCOS JL, FABBRINI G. et al. (1988). Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol, 24: 372-378.
64. Nutt JG, WOODWARD WR, HAMMERSTAD JP, CARTER JH, ADERSON JL. (1984). The on-off phenomenon in Parkinson's disease. N Engl J Med, 310: 483-488.
65. PARKES JD, ZILKHA KJ, CALVER DM, KNILL-JONES RP. (1970). Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet, 1: 259-262.
66. PATRICK D, DYO R. (1989). Generic and disease specific measures in accessing health status and quality of life, Med Care, Suppl 27: 217-232.
67. PETO V, JENKINSON C, FITZPATRICK R, GREENHALL R. (1995). The development and validation of a short measure of functionning and well-being for individuals with Parkinson's disease. Qual Life Res, 4: 241-248.
68. PETO V, JENKINSON C, FITZPATRICK R. (1998). PDQ-39 : a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol, 245, Suppl 1: S10-4.
69. RABEY JM, BASS H, BONUCELLI U, BROOKS D, KLOTZ P, KORCZYN AD, KRAUS P, MARTINEZ-MARTIN P, MORRISH P, VAN SAUTEN W, VAN HILTEN B. (1997). Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol, 20 (4): 322-337.
70. RADLOFF LS. (1977). The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement, 1: 385-401.
71. RICHARDS M, MARDER K, COTE L, MAYEUX R. (1994). Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord, 1: 89-91.
72. RIKLAN M, DILLER L. (1956). Certain psychomotor aspects of subtemporal pallidectomy for Parkinson's disease. J Am Geriat Soc, 4: 1258.
73. SCHWAB RS, ENGLAND AC. (1969). Projection technique for evaluating surgery in Parkinson's disease. In Gilligham FJ, Donaldson IML, eds. Third symposium on Parkinson's disease. Livingstone, Edinburgh, 152-157.
74. SHINDLER J, BROWN R, WELBURN P, PARKES J. (1988). Measuring the quality of life of paitents with Parkinson's disease. In Walker S, RosseR R. eds. Quality of life : assessment and applications. Lancaster: MTP Press.
75. SIMPSON GM, LEE JH, ZOUBOK B, GARDOS G. (1979). A rating scale for tardive dyskinesia. Psychopharmacology, 64: 171-179.
76. STARKSTEIN SE, MAYBERG HS, PREZIOSI TJ, ANDREZEJEWSKI MA, LEIGUARDA R., ROBINSON RG. (1992). Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatr Clin Neurosci, 4: 134-139.
77. STEBBINS GT, GOETZ CG. (1998). Factor structure of the Unified Parkinson's Disease Rating Scale: Motor Examination. Mov Disord, 13: 633-636.
78. STEWART AL, HAYS RD, WARE JE. (1988). The MOS short-form general health survey: reliability and validity in a patient population. Med Care, 26: 724-735.
79. TEYCHENNE PF, PFEIFFER RF, BERN SM, MCINTURFF D, CALNE DB. (1978). Comparison between lergotrile and pergolide in parkinsonism. Ann Neurol, 3: 319-324.
80. TISON F, BARBERGER-GATEAU P, DUBROCA B, HENRY P, DARTIGUES JF. (1997). Dependency in Parkinson's disease: a population-based survey in nondemented elderly subjects. Mov Disord, 12 (6): 910-915.
81. VAN HILTEN JJ, VAN DER ZWAN AD, ZWINDERMAN AH, ROOS RA. (1994). Rating impairment and disability in Parkinson's disease : evaluation of the Unified Parkinson's Disease Rating Scale. Mov Disord, 9 (1): 84-88.
82. WARE J, SHERBOURNE C. (1992). The MOS 36 items short form health survey : conceptual framework and item selection. Med Care, 39: 473-483.
83. WEBSTER DD. (1968). Clinical analysis of the disability in Parkinson's disease. Mod Treat, 5: 257-282.
84. WECHSLER D. (1981). Wechsler Adult Intelligence Scale-Revised. New York, NY: Psychological Corp.
85. WECHSLER D. (1987). Wechsler Memory Scale-Revised Manual. San Antonio, Tex: Psychological Corp.
86. WELBURN P, WALKER S. (1388). Assessment of quality of life in Parkinson's disease. In Telling Smith G, ed. Measuring health : a practical approach. London: John Wiley.
87. WIDNER H, DEFER GL. (1999). Dyskinesias assessment: from CAPIT to CAPSIT. Mov Disord, 14, Suppl 1: 60-66.
88. WOOD PHN. (1980). ed. WHO international classification of impairments, disabilities and handicaps. Geneva: World Health Organization.
89. ZIEGLER M, BLETON JP. (1990). Echelles d'évaluation de la maladie de Parkinson's. In Maladie de Parkinson et reeducation. Masson. Paris. 115-122.
90. ZIMMERMANN R, DEUSCHL G, HORNIG A, SCHULTE-MONTING J, FUCHS G, LUCKING CH. (1994). Tremors in Parkinson's disease : symptom analysis and rating. Clin Neuropharmacol, 17 (4): 303-314.